HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Characterization of human CD4(+) T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein.

Abstract
T cells must play the major role in controlling acute human Lassa virus infection, because patients recover from acute Lassa fever in the absence of a measurable neutralizing antibody response. T cells alone seem to protect animals from a lethal Lassa virus challenge, because after experimental vaccination no neutralizing antibodies are detectable. In order to study human T-cell reactivity to single Lassa virus proteins, the nucleoprotein (NP) of Lassa virus, strain Josiah, was cloned, expressed in Escherichia coli, and affinity purified. Peripheral blood mononuclear cells (PBMC) obtained from 8 of 13 healthy, Lassa virus antibody-positive individuals living in the Republic of Guinea, western Africa, were found to proliferate in response to the recombinant protein (proliferation index >/=10). PBMC obtained from one individual with a particularly high proliferative response were used to generate 50 NP-specific T-cell clones (TCC). For six of these the epitopes were mapped with overlapping synthetic peptides derived from the sequence of the NP. These CD4(+) TCC displayed high specific proliferation and produced mainly gamma interferon upon stimulation with NP. Because variation of up to 15% in the amino acid sequences of the structural proteins of naturally occurring Lassa virus variants has been observed, the reactivity of the TCC with peptides derived from the homologous epitopes of the Nigeria strain of Lassa virus and of the eastern Africa arenavirus Mopeia was tested. With the Nigeria strain of Lassa virus the levels of homology were 100% for two of these epitopes and 85% for three of them, whereas homology with the respective Mopeia epitopes ranged from 92 to 69%. Reactivity of the TCC with peptides derived from the variable epitopes of the Nigeria strain and of Mopeia was reduced or completely abolished. This report shows for the first time that seropositive individuals from areas of endemicity have very strong memory CD4(+) T-cell responses against the NP of Lassa virus, which are partly strain specific and partly cross-reactive with other Lassa virus strains. Our findings may have important implications for the strategy of designing recombinant vaccines against this mainly T-cell-controlled human arenavirus infection.
AuthorsJ ter Meulen, M Badusche, K Kuhnt, A Doetze, J Satoguina, T Marti, C Loeliger, K Koulemou, L Koivogui, H Schmitz, B Fleischer, A Hoerauf
JournalJournal of virology (J Virol) Vol. 74 Issue 5 Pg. 2186-92 (Mar 2000) ISSN: 0022-538X [Print] United States
PMID10666248 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Viral
  • Nucleoproteins
  • Peptides
  • Recombinant Proteins
  • Interferon-gamma
Topics
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Amino Acid Sequence
  • Antibodies, Viral (blood)
  • CD4-Positive T-Lymphocytes (immunology)
  • Clone Cells
  • Cloning, Molecular
  • Epitope Mapping
  • Escherichia coli
  • Female
  • Genes, Viral
  • Guinea
  • Humans
  • Interferon-gamma (analysis)
  • Lassa Fever (blood, immunology, virology)
  • Lassa virus (genetics, immunology, metabolism)
  • Lymphocyte Activation
  • Male
  • Middle Aged
  • Molecular Sequence Data
  • Nucleoproteins (biosynthesis, chemistry, immunology)
  • Peptides (chemistry)
  • Recombinant Proteins (biosynthesis)
  • Sequence Alignment
  • Sequence Homology, Amino Acid
  • Seroepidemiologic Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: